Key information

We innovate diagnostic efficiency

Key highlights

7* tests contributing to saving costs and protecting life

USD 1.8bn serviceable market with 5-10% annual growth

Entered partnerships with 5 major global IVD companies

Scalable, lean and flexible commercial model 

Delivered ~30% annual revenue growth 2019-23

2 ‘blockbuster’ tests in market and product development

Industry leading team and knowhow

Team with proven track-record and industry expertise from market leading IVD companies


Gentian’s strategy for long-term growth and value creation

Gentian Diagnostic’s purpose is to deliver efficient diagnostics for better treatment decisions.

The growing diagnostics market puts increasing pressure on clinical laboratory efficiency. However, many of the existing, clinically relevant biomarkers are available only on slow and inefficient platforms. Gentian’s solution is to utilise PETIA (Particle-Enhanced Turbidimetric Immunoassays), based on proprietary nanoparticle technology and knowhow, to convert existing biomarkers to the most efficient automated, high-throughput analysers.

Gentian’s portfolio of high-impact diagnostic tests targets several large and growing disease areas such as infections and inflammation, kidney failure and congestive heart failure. The company has four established products – Cystatin C, fCAL® turbo, Canine CRP and fPELA® turbo – that contributed to 30% annual revenue growth in 2019-2023. The most recent launch in Q3 2023 of Retinol-Binding Protein (RBP) will support growth for this category. In addition, GCAL® has been launched and is in market development while NT-proBNP is in the product development phase – with the two latter having potential to become growth accelerators. The company also has undisclosed projects in exploration and ‘proof of concept’ phases.

The company’s roadmap for long-term growth and value creation is founded on six strategic pillars:

  • Grow annual revenue from the company’s established products by 20%+ annually – by expanding market access through additional commercial partners and regulatory approvals.
  • Demonstrate clinical relevance of GCAL® for the early detection of severe infections.
  • Bring a steady stream of new high-impact diagnostic tests to market.
  • Secure one new contract with a global commercial partner every year, building on already established partnerships with major diagnostic companies across products.
  • Grow gross margin from ~50% to 60%+ through economies of scale.
  • Deliver long-term EBITDA margins of 40% through operational leverage and cost discipline.


*5 established tests, 1 in market development and further 1 in product development.

Subscribe to Stock Exchange Releases

Gentian Diagnostics ASA - Prospectus


IR Contact

Njaal Kind
CFO, Gentian Diagnostics ASA
+47 91906525

Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.